MAP3K13/LZK

Leucine Zipper-bearing Kinase (LZK, MAP3K13) is a member of the mixed lineage kinase family, sharing high sequence identity with Dual Leucine Zipper Kinase (DLK, MAP3K12) and functioning as a mitogen-activated protein kinase kinase kinase (MAP3K)^[1]. LZK activates JNK signaling through MKK4 and regulates neuronal axon growth and regeneration in mammalian central nervous system neurons^[1][2]. In Purkinje cells, LZK activation induces slow degeneration via caspase-mediated apoptosis, contrasting with the rapid degeneration triggered by DLK^[3]. LZK also promotes astrocyte reactivity and glial scar formation after CNS injury, modulating lesion size and influencing post-injury repair^[4]. Mechanistically, LZK participates in multicellular injury responses, functioning in both neurons and glia to regulate axon sprouting, regeneration, and scar formation^[5][6]. Compared with DLK, LZK exhibits slower kinetics in cell death induction and distinct contributions to regenerative versus degenerative pathways^[3][2]. In cancer contexts, MAP3K13 expression can be regulated by long noncoding RNAs or circular RNAs, influencing NF-κB signaling, pyroptosis, and tumor progression in gastric and colon adenocarcinomas^[7][8]. LZK inhibition or targeted degradation via PROTACs has demonstrated efficacy in suppressing head and neck squamous cell carcinoma growth by reducing c-MYC and gain-of-function p53 stability^[9][10]. Therefore, LZK represents a multifunctional MAP3K with isoform-specific effects and translational potential in both neurodegeneration and oncology research.